toxylact: a07a intestinal antiinfectives

The first professional lActological database in the word

This monograph summarizes lactation related toxicology for medicines classified in ATC subgroup A07A “Intestinal antiinfectives”, focusing on maternal use during breastfeeding and potential effects in breastfed infants.atcddd.fhi+2

Subgroup definition and composition

A07A belongs to ATC group A07 (antidiarrheals, intestinal anti inflammatory/anti infective agents) and comprises locally acting intestinal antiinfectives.atcddd.fhi+2
According to current ATC descriptions, A07A is subdivided into antibiotics (A07AA), sulfonamides (A07AB), imidazole derivatives (A07AC) and other intestinal antiinfectives (A07AX).bionity+2

Representative agents and mechanisms

The antibiotics subgroup (A07AA) includes orally administered formulations of agents such as vancomycin and colistin, used primarily for enterocolitis and other intestinal infections, and older local antibiotics like neomycin and polymyxin B.atcddd.fhi+2
Sulfonamides and imidazole derivatives contain locally acting chemotherapeutic agents; “other intestinal antiinfectives” may include non systemic rifamycin based products that act in the gut lumen with minimal systemic absorption.kegg+2

Pharmacokinetic features relevant to lactation

Most A07A medicines are formulated to act locally in the intestinal tract, and many show poor systemic bioavailability when given orally, which tends to limit their passage into breast milk.drugbank+2
However, factors such as dose, treatment duration, mucosal integrity, and individual variability can increase systemic absorption, so milk transfer cannot be assumed negligible for all agents within this subgroup.mydoctor.kaiserpermanente+2
Breast milk transfer and infant exposure
General lactation pharmacology principles indicate that medicines with low oral bioavailability, high protein binding, and short half life are less likely to reach clinically significant levels in breast milk and in the infant.medsafe+1
Because many A07A drugs remain largely within the gut lumen, relative infant dose via breast milk is expected to be low for typical short course treatments, although robust milk level data are lacking for many individual substances.mayoclinic+2

Potential risks to breastfed infants

Potential adverse effects in breastfed infants mainly involve gastrointestinal symptoms such as diarrhea, alterations of bowel flora, or, more rarely, antibiotic associated colitis.medsafe+1
Theoretical risks include selection of resistant intestinal bacteria and, for some antibiotics or sulfonamides with meaningful systemic absorption, effects on infant microbiota, rare hypersensitivity reactions, or interference with bilirubin binding in very young or premature infants.clevelandclinic+2

Maternal benefits and clinical indications

A07A medicines are used to treat enterocolitis and localized intestinal infections, which, when effectively managed, help preserve maternal hydration, nutritional status and overall health during lactation.atcddd.fhi+2
In many cases, effective local treatment allows continued breastfeeding, avoiding the need for systemic therapy or interruption of lactation, provided infant risk is assessed and monitored.aap+2

Use during breastfeeding: general recommendations

Most guidelines state that the majority of maternal medications can be used during breastfeeding, with only a small number being absolutely contraindicated; decisions should be individualized using drug specific lactation data whenever available.aap+2
For A07A drugs, short term use at the lowest effective dose, preference for molecules with minimal systemic absorption, and routine infant monitoring are reasonable risk management strategies for otherwise healthy term infants.mayoclinic+2

Higher risk situations and precautionary measures

Premature infants, neonates, or those with significant comorbidities (e.g. severe jaundice, gut disease, or immune compromise) may be more susceptible to disturbances of intestinal flora or drug related adverse effects and warrant extra caution.aap+2
In such cases, clinicians should carefully weigh the need for A07A therapy against alternative approaches, consider consulting specialized lactation resources, and intensify infant follow up.medsafe+2

Monitoring and counselling of breastfeeding dyads

Healthcare professionals should advise caregivers to observe breastfed infants for changes in stool pattern, feeding difficulties, excessive irritability or lethargy, and signs of allergic reactions while the mother receives an A07A medicine.mayoclinic+1
Documenting maternal therapy, explaining expected benefits and possible risks, and ensuring easy access to medical review in case of infant symptoms support safe use of intestinal antiinfectives during lactation.mydoctor.kaiserpermanente+2

Data limitations and need for further research

For many individual A07A agents, published pharmacokinetic studies measuring breast milk concentrations and relative infant dose are limited, and current recommendations often rely on extrapolation from systemic use or related drug classes.medsafe+1
Prospective clinical studies evaluating infant outcomes and microbiome changes after maternal exposure to locally acting intestinal antiinfectives would strengthen the evidence base for lactation specific risk assessment.mayoclinic+1

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.